Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been assigned an average recommendation of “Reduce” from the five analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have issued a hold rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $8.00.

BHC has been the subject of a number of research analyst reports. Royal Bank Of Canada decreased their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a report on Monday, April 27th. Weiss Ratings cut shares of Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 4th.

Bausch Health Cos Trading Up 0.5%

NYSE BHC opened at $4.92 on Friday. Bausch Health Cos has a 52 week low of $4.57 and a 52 week high of $8.69. The company has a 50 day moving average price of $5.24 and a 200 day moving average price of $5.79. The company has a quick ratio of 0.97, a current ratio of 1.32 and a debt-to-equity ratio of 54.68. The firm has a market cap of $1.84 billion, a PE ratio of -1.52 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). Bausch Health Cos had a negative return on equity of 2,922.77% and a negative net margin of 11.47%.The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion. As a group, sell-side analysts forecast that Bausch Health Cos will post 4.05 EPS for the current fiscal year.

Insider Buying and Selling at Bausch Health Cos

In other news, Director Frank D. Lee sold 24,456 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $5.43, for a total transaction of $132,796.08. Following the completion of the transaction, the director directly owned 49,339 shares of the company’s stock, valued at $267,910.77. This represents a 33.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Bausch Health Cos

Hedge funds have recently made changes to their positions in the company. Paulson & CO. Inc. lifted its position in shares of Bausch Health Cos by 3.5% in the fourth quarter. Paulson & CO. Inc. now owns 73,255,869 shares of the company’s stock valued at $509,128,000 after acquiring an additional 2,500,000 shares in the last quarter. Goldentree Asset Management LP lifted its stake in shares of Bausch Health Cos by 1.7% in the third quarter. Goldentree Asset Management LP now owns 34,833,431 shares of the company’s stock worth $224,409,000 after buying an additional 578,542 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Bausch Health Cos by 24.9% during the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock worth $61,362,000 after purchasing an additional 2,262,894 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Bausch Health Cos by 65.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 5,143,641 shares of the company’s stock worth $35,748,000 after buying an additional 2,038,813 shares during the last quarter. Finally, Norges Bank purchased a new stake in Bausch Health Cos in the 4th quarter valued at $25,592,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.